Earlier R&D Programs, Maturing Candidates Emerge From Bristol’s Pipeline
Mid-Stage Milvexian Cleared First Proof-Of-Concept Hurdle
BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.
You may also be interested in...
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.
Evotec's CEO and Takeda’s president of R&D provide insights around how India could shape its efforts to accelerate biopharma innovation. Backing the right technologies, fostering a culture to "stop losses" early on for projects that don't work and learning from China’s overhaul of its healthcare system were among the key takeaways.